AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb vaccine for seropositive children
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine for seropositive children
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz vaccine for seropositive children
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 8-10 months
Number of subjects: 5
Study 2574304 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz vaccine at 8-10 months
Number of subjects: 5
Study 29448880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing single-radius TKP
Number of subjects: 46
Study 29448880 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing single-radius TKP
Number of subjects: 46
Study 26939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 30% (Xe/O2 30%/60%)
Number of subjects: 24
Study 26939898 — intervention group
Group type: COMPARATOR
Intervention: Control gas (N2/O2 40%/60%)
Number of subjects: 24
Study 24589938 — intervention group
Group type: COMPARATOR
Intervention: Video computer tailoring (n=670)
Number of subjects: 2099
Study 24589938 — intervention group
Group type: COMPARATOR
Intervention: Text computer tailoring (n=708)
Number of subjects: 2099
Study 24589938 — intervention group
Group type: EXPERIMENTAL
Intervention: Control condition (n=721)
Number of subjects: 2099
Study 22364371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully and protagonist‐perspective labeled conditions
Number of subjects: 165
Study 22364371 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling the nondominant belief
Number of subjects: 165
Study 22364371 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling manipulations
Number of subjects: 165
Study 19833566 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LAP) plus steroids
Number of subjects: 18
Study 19032173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g piperacillin
Number of subjects: 10
Study 19032173 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g piperacillin
Number of subjects: 10
Study 15927814 — intervention group
Group type: EXPERIMENTAL
Intervention: FX cream (0.02% farnesol and 5% xylitol)
Number of subjects: 17
Study 15927814 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 17
Study 12831141 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (topically applied once daily in the evening for 12 weeks)
Number of subjects: 28
Study 12831141 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine (applied twice daily for 6 weeks, with 16 patients continuing for 12 weeks)
Number of subjects: 28
Study 12831141 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28
Study 12831141 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 28
Study 11322147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar corset
Number of subjects: 12
Study 11322147 — intervention group
Group type: COMPARATOR
Intervention: No lumbar corset
Number of subjects: 12
Study 8796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50 micrograms)
Number of subjects: 24
Study 8796775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 24
Study 8796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (fentanyl and control)
Number of subjects: 24
Study 8382104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for an average of 8 days)
Number of subjects: 20
Study 8382104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 3654235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐Asma Control y Tratamiento Para Niños (asthma educational program)
Number of subjects: 0
Study 29582517 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motivational interviewing (3 individual sessions by nurses or social workers prior to hospital discharge)
Number of subjects: 48
Study 29582517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 28712152 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (HP) with LED blue/laser infrared activation
Number of subjects: 31
Study 28712152 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (HP) control
Number of subjects: 31
Study 27045127 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation combined with Stress Management Training (CR+SMT)
Number of subjects: 151
Study 27045127 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR) alone
Number of subjects: 151
Study 27045127 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR) groups (both CR and CR+SMT)
Number of subjects: 151
Study 23816022 — intervention group
Group type: EXPERIMENTAL
Intervention: Canada Acute Coronary Syndrome Risk Score (C-ACS)
Number of subjects: 0
Study 23816022 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ACS score of 0
Number of subjects: 0
Study 22156181 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional written information about orthodontic treatment
Number of subjects: 80
Study 22156181 — intervention group
Group type: COMPARATOR
Intervention: Additional written information about fluoride
Number of subjects: 80
Study 20112575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheezheng Qingpeng ointment
Number of subjects: 78
Study 20112575 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac diethylamine emugel
Number of subjects: 78
Study 16936533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fixed combination of perindopril 2 mg and indapamide 0.625 mg
Number of subjects: 12140
Study 16936533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based glucose control regimen targeting HbA1c of 6.5% or less
Number of subjects: 12140
Study 16936533 — intervention group
Group type: COMPARATOR
Intervention: Standard guidelines based therapy for glucose control
Number of subjects: 12140
Study 15495877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural cancer patients
Number of subjects: 0
Study 15495877 — intervention group
Group type: COMPARATOR
Intervention: Urban cancer patients
Number of subjects: 0
Study 11783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal anticellulite pill plus supplements of conjugated linoleic acid
Number of subjects: 60
Study 11783459 — intervention group
Group type: COMPARATOR
Intervention: Herbal anticellulite pill
Number of subjects: 60
Study 9051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL) implantation through a 3.2 mm incision
Number of subjects: 120
Study 9051503 — intervention group
Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) IOL implantation through a 4.0 mm incision
Number of subjects: 120
Study 9051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (3.2 mm and 4.0 mm incisions)
Number of subjects: 120
Study 1651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 1 reassortant vaccine (10^4 p.f.u.)
Number of subjects: 100
Study 1651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 2 reassortant vaccine (10^4 p.f.u.)
Number of subjects: 100
Study 1651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serotype 1 and serotype 2 vaccines (0.5 x 10^4 p.f.u. of each)
Number of subjects: 100
Study 1651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent combination (0.33 x 10^4 p.f.u. of each strain)
Number of subjects: 100
Study 1651610 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study 1651610 — intervention group
Group type: EXPERIMENTAL
Intervention: Various vaccines and combinations
Number of subjects: 100
Study 6321376 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ORG 2766
Number of subjects: 45
Study 6321376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30883053 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with a self-expanding supraannular bioprosthesis
Number of subjects: 1403
Study 30883053 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1403
Study 30883053 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1403
Study 30883053 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1403
Study 27659218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 24
Study 27659218 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 24
Study 27659218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 24
Study 27659218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25132516 — intervention group
Group type: COMPARATOR
Intervention: PEGASUS psychoeducational programme (n = 24), administered in six weekly group sessions.
Number of subjects: 48
Study 25132516 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no additional intervention (n = 24).
Number of subjects: 48
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous inhibitor clearance in patients not undergoing ITI
Number of subjects: 524
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor titre and gene mutation
Number of subjects: 524
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of inhibitors
Number of subjects: 524
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent inhibitors
Number of subjects: 524
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient inhibitors
Number of subjects: 524
Study 24001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional category of patients
Number of subjects: 524
Study 21860049 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Affect Recognition (TAR)
Number of subjects: 38
Study 21860049 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation Training (CRT)
Number of subjects: 38
Study 19922681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination reverse transcriptase inhibitors
Number of subjects: 0
Study 17257428 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion for 90 minutes
Number of subjects: 7
Study 17257428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 15508665 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing through a face mask with an ITD (impedance of 6 cm H2O)
Number of subjects: 20
Study 15508665 — intervention group
Group type: COMPARATOR
Intervention: Breathing through a face mask with a sham ITD (control)
Number of subjects: 20
Study 11869325 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (80 units in five cases, 60 units in two cases) into four quadrants of lower esophageal sphincter (LES)
Number of subjects: 17
Study 11869325 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation by Rigiflex dilator
Number of subjects: 17
Study 11869325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (BT and pneumatic dilatation)
Number of subjects: 17
Study 11869325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dysphagia-free state
Number of subjects: 17
Study 9272237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg intravenously
Number of subjects: 12
Study 9272237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan combined with ethanol orally
Number of subjects: 12
Study 9272237 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.8 g/kg alone
Number of subjects: 12
Study 8591371 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based medical record (intervention group); 191 patients
Number of subjects: 349
Study 8591371 — intervention group
Group type: COMPARATOR
Intervention: Control group; 158 patients
Number of subjects: 349
Study 8591371 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based medical record (intervention group)
Number of subjects: 349
Study 8591371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study 2688125 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzen (Serrapeptase)
Number of subjects: 70
Study 2688125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1169822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextran 40
Number of subjects: 271
Study 1169822 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 271
Study 1169822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 271
Study 31546613 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation and Therapeutic Exercises (FES+TE)
Number of subjects: 5
Study 31546613 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Exercises (TE)
Number of subjects: 5
Study 28409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 49
Study 28409563 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact waitlist
Number of subjects: 49
Study 28409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined OCD participants (CBT-only plus waitlist-CBT)
Number of subjects: 49
Study 28409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CBT Glu levels in vPCC
Number of subjects: 49
Study 25982235 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group (knee flexed at 45°)
Number of subjects: 100
Study 25982235 — intervention group
Group type: COMPARATOR
Intervention: Extension group (knee fully extended)
Number of subjects: 100
Study 25982235 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group
Number of subjects: 100
Study 25982235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 24052987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day for at least 6 months)
Number of subjects: 14
Study 25665208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of 5 mg x kg(‐1) of body weight of caffeine and 200 mg of Panax ginseng
Number of subjects: 9
Study 25665208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19909587 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole, 5 mg/day) + rFSH (450 IU/day)
Number of subjects: 70
Study 19909587 — intervention group
Group type: COMPARATOR
Intervention: rFSH (450 IU/day) alone
Number of subjects: 70
Study 16802289 — intervention group
Group type: EXPERIMENTAL
Intervention: EMF-on (real exposure)
Number of subjects: 15
Study 16802289 — intervention group
Group type: COMPARATOR
Intervention: EMF-off (sham exposure)
Number of subjects: 15
Study 16802289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic temperature
Number of subjects: 15
Study 15564955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 0.5-4 mg
Number of subjects: 2468
Study 15564955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 1 mg
Number of subjects: 2468
Study 15564955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2 mg
Number of subjects: 2468
Study 15564955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 4 mg
Number of subjects: 2468
Study 15564955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg
Number of subjects: 2468
Study 10673291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple antibiotic therapy for one day
Number of subjects: 121
Study 10673291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple antibiotic therapy for two days
Number of subjects: 121
Study 10673291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cagA+/vacA s1 H pylori strains
Number of subjects: 121
Study 10673291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with peptic ulcer disease
Number of subjects: 121
Study 9300248 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasting plasma NEFA in NGT subjects
Number of subjects: 4089
Study 9300248 — intervention group
Group type: EXPERIMENTAL
Intervention: High 2-h plasma NEFA and low 2-h plasma insulin concentrations in IGT subjects
Number of subjects: 4089
Study 9300248 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NEFA concentration at baseline
Number of subjects: 4089
Study 9300248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h plasma insulin concentration in subjects with IGT who deteriorated
Number of subjects: 4089
Study 8449086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 percent sodium citrate
Number of subjects: 40
Study 8449086 — intervention group
Group type: COMPARATOR
Intervention: Heparin 4 U/ml
Number of subjects: 40
Study 3518910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 200 mg intramuscularly weekly for 4 weeks
Number of subjects: 0
Study 3518910 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 0
Study 30167699 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 3004
Study 30167699 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 3004
Study 27283930 — intervention group
Group type: EXPERIMENTAL
Intervention: OSEM reconstruction for pre- and posttherapeutic PET (OSEMPET1/OSEMPET2)
Number of subjects: 86
Study 27283930 — intervention group
Group type: EXPERIMENTAL
Intervention: PSF ± TOF reconstruction for pre- and OSEM reconstruction for posttherapeutic PET (PSF ± TOFPET1/OSEMPET2)
Number of subjects: 86
Study 27283930 — intervention group
Group type: COMPARATOR
Intervention: PSF ± TOF reconstruction for pre- and posttherapeutic PET (PSF ± TOFPET1/OSEMPET2)
Number of subjects: 86
Study 27283930 — intervention group
Group type: COMPARATOR
Intervention: OSEM reconstruction for pre- and PSF ± TOF reconstruction for posttherapeutic PET (OSEMPET1/PSF ± TOFPET2)
Number of subjects: 86
Study 27283930 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary software tool applied to PSF ± TOF data
Number of subjects: 86
Study 24635110 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with TheraBite(®) Jaw Motion Rehabilitation System(™)
Number of subjects: 66
Study 24635110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 66
Study 24635110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving 3D conformal radiotherapy
Number of subjects: 66
Study 24635110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with RT and concurrent chemotherapy
Number of subjects: 66
Study 22221565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES
Number of subjects: 4423
Study 22221565 — intervention group
Group type: COMPARATOR
Intervention: High SES
Number of subjects: 4423
Study 22221565 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 4423
Study 22221565 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 4423
Study 20546509 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 181
Study 20546509 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg/day (for previously placebo-treated patients)
Number of subjects: 181
Study 17563335 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of IGFBP-1 at admission
Number of subjects: 1253
Study 17563335 — intervention group
Group type: EXPERIMENTAL
Intervention: ln updated mean blood glucose
Number of subjects: 1253
Study 17563335 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (+5 years)
Number of subjects: 1253
Study 17563335 — intervention group
Group type: EXPERIMENTAL
Intervention: ln serum creatinine at admission
Number of subjects: 1253
Study 17563335 — intervention group
Group type: EXPERIMENTAL
Intervention: ln IGFBP-1 at admission
Number of subjects: 1253
Study 15809017 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g oral arginine
Number of subjects: 8
Study 15809017 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g oral arginine
Number of subjects: 8
Study 15809017 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 g oral arginine
Number of subjects: 8
Study 15809017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11977435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia
Number of subjects: 51
Study 10084473 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 42 microg, twice daily
Number of subjects: 0
Study 10084473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids devoid of tryptophan
Number of subjects: 25
Study 7726319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (amino acid drink containing tryptophan)
Number of subjects: 25
Study 2257960 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratia peptidase (two tablets three times a day for 7-8 days)
Number of subjects: 193
Study 2257960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets three times a day for 7-8 days)
Number of subjects: 193
Study 473837 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment
Number of subjects: 49
Study 31403339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental contrasting with implementation intentions (MCII)
Number of subjects: 604
Study 31403339 — intervention group
Group type: COMPARATOR
Intervention: Motivationally-relevant control exercise
Number of subjects: 604
Study 31403339 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control group
Number of subjects: 604
Study 30819262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (38 µg or 1500 IU daily) with iron-fortified breakfast cereal
Number of subjects: 50
Study 30819262 — intervention group
Group type: COMPARATOR
Intervention: Placebo with iron-fortified breakfast cereal
Number of subjects: 50
Study 28535235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin plus trimethoprim‐sulfamethoxazole (500 mg 4 times daily, plus 320 mg/1600 mg twice daily for 7 days)
Number of subjects: 500
Study 28535235 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin alone (500 mg 4 times daily for 7 days)
Number of subjects: 500